Angiodynamics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
AngioDynamics, Inc. filed a definitive proxy statement (DEFA14A) with the U.S. Securities and Exchange Commission.
NASDAQ
AngioDynamics, Inc. announced its 2025 Annual Meeting agenda, including director elections and executive compensation votes, alongside fiscal year 2025 performance highlights showing strategic transformation progress.
NASDAQ
AngioDynamics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pursuant to Section 14(a) of the Securities Exchange Act of 1934.
NASDAQ
AngioDynamics is asking shareholders to approve an amendment to its 2020 Equity Incentive Plan to increase the number of shares available for issuance.